
Hematology-Oncology Physician, Interested in Lymphoma/BMT/cell therapy | Alum @roswellpark @cookcountyIMR
United States
Joined September 2017
- Tweets551
- Following1.6K
- Followers379
- Likes2.6K
Muhammad Junaid Tariq retweeted
Management of advanced mycosis fungoides and Sézary Syndrome: International Recommendations
@AnnaSureda5
onlinelibrary.wiley.com/doi/…
Muhammad Junaid Tariq retweeted
👀 The UF Health Cancer Institute will be well-represented at #ASH26. Come see our @UF team at booth #2622 in the exhibition hall! #UF_ASH26
📢 The wait is over: Abstracts for the 68th ASH Annual Meeting and Exposition are live!
More than 6,300 abstracts have been accepted for oral and poster presentations at #ASH26.
Browse now: ow.ly/5VCp5103LAa
#Hematology #HemeOnc
Muhammad Junaid Tariq retweeted
Meta-analysis of 16 studies of allo v auto SCT for ENKTL:
- PFS and OS higher for auto
- Response rate higher for allo, but increased TRM
- Lots of heterogeneity between studies, except for OS estimates post auto (I² 0.1 in this group) & RR post allo
Allogeneic versus autologous stem cell transplantation for extranodal NK/T-Cell lymphoma: A systematic review and meta-analysis | Bone Marrow Transplantation share.google/4oNngoqubKnMWmt…
Muhammad Junaid Tariq retweeted
My advice for the newish interns.
Take responsibility.
The right mentality, nothing will happen unless I do it. Check everything with the source, patient and raw data (labs, imaging reports etc).
Do not trust anyone (sometimes even your attending) and independently verify.
Muhammad Junaid Tariq retweeted
Honored to be part of this @DanaFarberNews @SylvesterCancer collaboration led by @JenCrombieMD, now out in @BloodPortfolio
Glofit + Pola-R-CHP in untreated DLBCL (IPI ≥2):
- 95% CR
- 24-mo PFS 95%
- CRS 10%, all grade 1
- No ICANS
ashpublications.org/blood/ar…
Muhammad Junaid Tariq retweeted
Fascinating to hear the patient voice for nodular LP Hodgkin. We often say it’s very low risk, very good outcomes. And that’s true for most. But lack of certainty for the individual is a real a problem. #ISHL14 @JamieFlerlage
Muhammad Junaid Tariq retweeted
👉👉 👉 Summary slide. Grade 3-4 neutropenia and thrombocytopenia, and grade 3+ infections in selected firstline CLL trials
@UTMDAnderson
👉👉👉 A summary slide detailing MRD responses at approx 1 yr of combination (doublets and triplets) at different MRD thresholds in Firstline CLL @UTMDAnderson
Muhammad Junaid Tariq retweeted
👉👉👉 A summary slide detailing MRD responses at approx 1 yr of combination (doublets and triplets) at different MRD thresholds in Firstline CLL @UTMDAnderson
Muhammad Junaid Tariq retweeted
Amazing progress in treatment of Hodgkin lymphoma: From nearly no survivors to nearly all, since the 1960’s. Coincides with the career of Volker Diehl. #ISHL-14
Muhammad Junaid Tariq retweeted
Happy to present at #ISHL2026 in cologne on the challenges with treating elderly patients with some take home messages
Muhammad Junaid Tariq retweeted
This excellent manuscript from @pbachi gives some answers about why allogeneic car t sometimes fails. Two categories: 1. Pre-existing patient immune responses that attack the donor CAR T and to me surprising 2. Effectors>stem-like (different from auto!). pubmed.ncbi.nlm.nih.gov/4278…
Muhammad Junaid Tariq retweeted
We just reported our experience with steroid or anakinra prophylaxis in patients with high ferritin/CRP receiving axi-cel for DLBCL 1/n
pubmed.ncbi.nlm.nih.gov/4280…
Muhammad Junaid Tariq retweeted
#Hematology The chaos of choice in large B-cell #lymphoma: a call to harmonize first-line trials
#lymsm
ashpublications.org/blood/ar…
Muhammad Junaid Tariq retweeted
#IMS2026 How to approach first relapse by @DrRakeshPopat
Muhammad Junaid Tariq retweeted
UF Health Cancer Institute member Dina Khalaf, M.D., (@dgkhalaf) was interviewed for a segment of the @cure_today Clinical Trial Corner. She shares her expertise on three trials shaping the future of care for patients with AML and MDS.
Watch the video: curetoday.com/view/3-trials-…
Impact of Vincristine Dose Reduction on Outcomes of Patients With Advanced-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP
onlinelibrary.wiley.com/doi/…
Muhammad Junaid Tariq retweeted
Mandating computer physician orders entry is one of the most destructive policies in healthcare.
It’s the biggest factor that tethered the physician to the computer.
If a patient needs a CT scan, the doctor can’t just put it in the note or tell a nurse. The doctor has to take the time to click through the cumbersome order entry.
It creates a culture where doctors are admonished and pestered about orders, even when the intent is perfectly clear and documented in the record.
Patient decided they want their CT scan at another location? “Doctor, you need to re order the scan.”
Patient wants to change their surgery date? “Doctor, you need to put in a new order.”
“You ordered this lab wrong. You need to fix it.” “There is a new order set for this medication. You need to use that.” “Speech therapy says the patient can eat. You need to put the order in.”
This adds up to a huge burden on doctors. Every little thing requires many clicks in the computer.
It all adds up. We researched this at ucsf and found the neurosurgeons were spending 2 hours a day just on order entry. Not notes, imaging review, or in the OR.
Just orders. And that doesn’t count the time it takes to find an open (and working) computer, log in, and find the chart.
Other studies have estimated between 15-30 full workdays are consumed annually just in order entry.
That’s an entire month of doctor time gone just to click through the computer.
I’m not saying we go back to chicken scratch on a pad of paper.
But if the doctor note says “patient needs CT of the head” why do we require another 40 clicks? If a doctor is running to the OR, why cant a verbal order suffice? If a surgery was already booked correctly once, why does the doctor need to re enter it completely?
Imagine how much more time doctors would have to treat patients if we simply reversed that rule.
Muhammad Junaid Tariq retweeted
B-Cell vs T-Cell Lymphoma: The FDA Approval Gap @SocietyofHemOnc @SOHO26


































